624 related articles for article (PubMed ID: 23845225)
1. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J
Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015
[TBL] [Abstract][Full Text] [Related]
3. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.
Chen S; Dai X; Gao Y; Shen F; Ding J; Chen Q
Sci Rep; 2017 Dec; 7(1):16922. PubMed ID: 29208958
[TBL] [Abstract][Full Text] [Related]
4. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma.
Fujimura M; Hidaka T; Kataoka K; Yamakawa Y; Akada S; Teranishi A; Saito S
Am J Surg Pathol; 2001 May; 25(5):667-72. PubMed ID: 11342781
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
6. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
8. HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.
Geisler JP; Tammela JE; Manahan KJ; Geisler HE; Miller GA; Zhou Z; Wiemann MC
Eur J Gynaecol Oncol; 2004; 25(2):165-8. PubMed ID: 15032273
[TBL] [Abstract][Full Text] [Related]
9. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
[TBL] [Abstract][Full Text] [Related]
10. Hormone receptors and ovarian cancer survival.
Gourley C
Lancet Oncol; 2013 Aug; 14(9):794-5. PubMed ID: 23845224
[No Abstract] [Full Text] [Related]
11. Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma.
Zwart J; Geisler JP; Geisler HE
Eur J Gynaecol Oncol; 1998; 19(3):225-8. PubMed ID: 9641218
[TBL] [Abstract][Full Text] [Related]
12. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.
Rambau PF; Vierkant RA; Intermaggio MP; Kelemen LE; Goodman MT; Herpel E; Pharoah PD; Kommoss S; Jimenez-Linan M; Karlan BY; Gentry-Maharaj A; Menon U; Polo SH; Candido Dos Reis FJ; Doherty JA; Gayther SA; Sharma R; Larson MC; Harnett PR; Hatfield E; de Andrade JM; Nelson GS; Steed H; Schildkraut JM; Carney ME; Høgdall E; Whittemore AS; Widschwendter M; Kennedy CJ; Wang F; Wang Q; Wang C; Armasu SM; Daley F; Coulson P; Jones ME; Anglesio MS; Chow C; de Fazio A; García-Closas M; Brucker SY; Cybulski C; Harris HR; Hartkopf AD; Huzarski T; Jensen A; Lubiński J; Oszurek O; Benitez J; Mina F; Staebler A; Taran FA; Pasternak J; Talhouk A; Rossing MA; Hendley J; ; Edwards RP; Fereday S; Modugno F; Ness RB; Sieh W; El-Bahrawy MA; Winham SJ; Lester J; Kjaer SK; Gronwald J; Sinn P; Fasching PA; Chang-Claude J; Moysich KB; Bowtell DD; Hernandez BY; Luk H; Behrens S; Shah M; Jung A; Ghatage P; Alsop J; Alsop K; García-Donas J; Thompson PJ; Swerdlow AJ; Karpinskyj C; Cazorla-Jiménez A; García MJ; Deen S; Wilkens LR; Palacios J; Berchuck A; Koziak JM; Brenton JD; Cook LS; Goode EL; Huntsman DG; Ramus SJ; Köbel M
J Pathol Clin Res; 2018 Oct; 4(4):250-261. PubMed ID: 30062862
[TBL] [Abstract][Full Text] [Related]
13. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
[TBL] [Abstract][Full Text] [Related]
14. Folate receptor alpha as a tumor target in epithelial ovarian cancer.
Kalli KR; Oberg AL; Keeney GL; Christianson TJ; Low PS; Knutson KL; Hartmann LC
Gynecol Oncol; 2008 Mar; 108(3):619-26. PubMed ID: 18222534
[TBL] [Abstract][Full Text] [Related]
15. Expression of estrogen-related receptors in ovarian cancer and impact on survival.
Schüler-Toprak S; Weber F; Skrzypczak M; Ortmann O; Treeck O
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2555-2567. PubMed ID: 34089362
[TBL] [Abstract][Full Text] [Related]
16. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
Köbel M; Atenafu EG; Rambau PF; Ferguson SE; Nelson GS; Ho TC; Panzarella T; McAlpine JN; Gilks CB; Clarke BA; Bernardini MQ
Gynecol Oncol; 2016 Jun; 141(3):559-563. PubMed ID: 27072807
[TBL] [Abstract][Full Text] [Related]
17. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
[TBL] [Abstract][Full Text] [Related]
19. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
Peres LC; Cushing-Haugen KL; Köbel M; Harris HR; Berchuck A; Rossing MA; Schildkraut JM; Doherty JA
J Natl Cancer Inst; 2019 Jan; 111(1):60-68. PubMed ID: 29718305
[TBL] [Abstract][Full Text] [Related]
20. GATA6: a new predictor for prognosis in ovarian cancer.
Shen W; Niu N; Lawson B; Qi L; Zhang J; Li T; Zhang H; Liu J
Hum Pathol; 2019 Apr; 86():163-169. PubMed ID: 30633927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]